ELQ-300

ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1) . ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial[1][2].

Product Specifications

CAS Number

[1354745-52-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/elq-300.html

Purity

98.0

Solubility

DMSO : 15.62 mg/mL (ultrasonic)

Smiles

O=C1C(C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2)=C(C)NC4=C1C=C(Cl)C(OC)=C4

Molecular Formula

C24H17ClF3NO4

Molecular Weight

475.84

Precautions

H302, H315, H319, H335

References & Citations

[1]Stickles AM, et al. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. Antimicrob Agents Chemother. 2015 Apr;59 (4) :1977-82.|[2]Stickles AM, et al. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother. 2016 Jul 22;60 (8) :4853-9.